New spinal fluid biomarker distinguishes Parkinson's and Lewy body dementia from Alzheimer's disease ++

Alpha synuclein reveals complexity behind Alzheimer’s and Parkinson’s diagnosis Alpha synuclein reveals complexity behind Alzheimer’s and Parkinson’s diagnosis Emerging data shows alpha synuclein may be present in the majority of neurodegenerative disease cases, reshaping how clinicians understand dementia and Parkinson’s. Written byBree Foster, PhD https://www.drugdiscoverynews.com/alpha-synuclein-reveals-complexity-behind-alzheimer-s-and-parkinson-s-diagnosis-17131?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--ojeZYW3JecThNXHeK_zRaQcz5h_ATu8jNRkq6Mb0w28LblzooaSk6CoIA68ethEWj1RrZZd20BBvOC9aE9NBlstdx6g&_hsmi=419012739&utm_content=419012739&utm_source=hs_email Neurodegenerative diseases are among the most complex and devastating conditions in medicine. They progress slowly, often silently, for years or even decades before symptoms become obvious — and by the time a patient reaches a specialist’s office, substantial and irreversible neuronal damage has already occurred. Today, more than 55 million people worldwide live with dementia, a figure projected to climb to roughly 140 million by 2050, with an estimated global cost of $1 trillion annually. New spinal fluid biomarker distinguishes Parkinson's and Lewy body dementia from Alzheimer's disease https://www.drugdiscoverynews.com/new-spinal-fluid-biomarker-distinguishes-parkinson-s-and-lewy-body-dementia-from-alzheimer-s-disease-17091?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8DlyTy7JdIlpfKmMGLEGhFfGoQR7p_jGfMd3Fg4h0EWVND9xkYPjwkWlni4mdB0uNwMx3_g_Eo3J2GM-aIUOzMtLwERg&_hsmi=419012739&utm_content=419012739&utm_source=hs_email New spinal fluid biomarker distinguishes Parkinson's and Lewy body dementia from Alzheimer's disease Immunoassays measuring DOPA decarboxylase in cerebrospinal fluid achieve high diagnostic accuracy. Written byAndrea Corona Diagnosing dementia with Lewy bodies (DLB) has long been one of neurology's more stubborn problems. The condition shares significant symptom overlap with Alzheimer's disease (AD) and other dementias, and misdiagnosis is common — with real consequences, since treatments effective for one condition can be harmful in another. A new study published in Nature Medicine may change that.